Literature DB >> 28199813

Antiretroviral Therapy for Perinatal HIV Prevention.

Mary G Fowler1, Lynne M Mofenson2, Taha E Taha3.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28199813     DOI： 10.1056/NEJMc1616287

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.

Authors:  Michael J Boivin; Limbika Maliwichi-Senganimalunje; Lillian W Ogwang; Rachel Kawalazira; Alla Sikorskii; Itziar Familiar-Lopez; Agatha Kuteesa; Mary Nyakato; Alex Mutebe; Jackie L Namukooli; MacPherson Mallewa; Horacio Ruiseñor-Escudero; Jim Aizire; Taha E Taha; Mary G Fowler
Journal:  Lancet HIV       Date:  2019-05-20       Impact factor: 12.767

2.  No Difference in Growth Outcomes up to 24 Months of Age by Duration of Exposure to Maternal Antiretroviral Therapy Among Children Who Are HIV-Exposed and Uninfected in Malawi.

Authors:  Gabriela Toledo; Megan Landes; Monique van Lettow; Beth A Tippett Barr; Heather Bailey; Claire Thorne; Siobhan Crichton
Journal:  Front Pediatr       Date:  2022-06-20       Impact factor: 3.569

3.  Targeted HIV testing at birth supported by low and predictable mother-to-child transmission risk in Botswana.

Authors:  Maryanne Ibrahim; Kenneth Maswabi; Gbolahan Ajibola; Sikhulile Moyo; Michael D Hughes; Oganne Batlang; Maureen Sakoi; Chloe Auletta-Young; Laura Vaughan; Shahin Lockman; Patrick Jean-Philippe; Xu Yu; Matthias Lichterfeld; Daniel R Kuritzkes; Joseph Makhema; Roger L Shapiro
Journal:  J Int AIDS Soc       Date:  2018-05       Impact factor: 6.707
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.